|Bid||0.00 x 900|
|Ask||0.00 x 1200|
|Day's range||162.82 - 164.57|
|52-week range||155.72 - 186.69|
|Beta (5Y monthly)||0.57|
|PE ratio (TTM)||24.26|
|Forward dividend & yield||4.52 (2.69%)|
|Ex-dividend date||17 Feb 2023|
|1y target est||N/A|
NEW BRUNSWICK, N.J., January 24, 2023--Johnson & Johnson (NYSE: JNJ) today announced results for fourth-quarter and full year 2022. "Our full year 2022 results reflect the continued strength and stability of our three business segments, despite macroeconomic challenges," said Joaquin Duato, Chairman of the Board and Chief Executive Officer. "I am inspired by our employees who make a difference in the health and lives of people around the world every day. As we look ahead to 2023, Johnson & Johns
NEW BRUNSWICK, N.J., January 18, 2023--Johnson & Johnson (NYSE: JNJ) will participate in the SVB Securities Global Biopharma Conference on Wednesday, February 15th. Biljana Naumovic, Worldwide Vice President, Oncology and Peter Lebowitz, Global Therapeutic Head, Oncology will represent the Company in a virtual session scheduled at 1:00 p.m. (Eastern Time).
NEW BRUNSWICK, N.J., December 22, 2022--Johnson & Johnson (NYSE: JNJ), the world’s largest, most diversified healthcare products company, today announced it has completed its acquisition of Abiomed, Inc. Abiomed is now part of Johnson & Johnson and will operate as a standalone business within Johnson & Johnson’s MedTech segment.